XML 110 R41.htm IDEA: XBRL DOCUMENT
v3.23.1

Associated companies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Statement [line items] |
Schedule disclosing information related to associates |
|  | Net income statement effect |  | Other comprehensive income effect 1 |  | Total comprehensive income effect |
(USD millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |
Roche Holding AG, Switzerland |  |  |  | 15 341 |  | 677 |  |  |  | 46 |  | -56 |  |  |  | 15 387 |  | 621 |
Others |  | -9 |  | -2 |  | -4 |  |  |  |  |  |  |  | -9 |  | -2 |  | -4 |
Associated companies |  | -9 |  | 15 339 |  | 673 |  |  |  | 46 |  | -56 |  | -9 |  | 15 385 |  | 617 |
1 In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.
Roche Holding AG, Switzerland |
Statement [line items] |
Schedule disclosing information related to associates, net income effect |
(USD millions) |  | 2021 |  | 2020 |
Novartis share of Roche's estimated current-year consolidated net income |  | 815 |  | 913 |
Prior-year adjustment |  | 40 |  | -64 |
Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million |  | -70 |  | -172 |
Gain on divestment of the investment in Roche 1 |  | 14 556 |  |  |
Net income effect |  | 15 341 |  | 677 |
1 The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.

X
- Definition The disclosure of associates. [Refer: Associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2022-03-24 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2022-03-24 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard -URIDate 2022-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B4 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_StatementLineItems
Namespace Prefix: | nvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |